Information Provided By: 
Fly News Breaks for January 30, 2018
LJPC
Jan 30, 2018 | 10:19 EDT
H.C. Wainwright analyst Edward White noted that La Jolla established a wholesale acquisition cost of $1,500 per vial for Giapreza. He estimates this will translate to a WAC cost of a little over $3,000 for one course of therapy, which is below his previous assumption of $5,000 per course of therapy. However, Giapreza received a broader label than he expected, which increased the target population by 50%, said White, who keeps a Buy rating and $91 price target on La Jolla shares.
News For LJPC From the Last 2 Days
There are no results for your query LJPC
